Navigation Links
Watson Third Quarter 2011 Net Revenue Climbs 23% to $1.1 Billion; Non-GAAP Diluted EPS of $1.09; GAAP Diluted EPS of $0.54
Date:11/1/2011

tments

7.3-10.011.8Acquisition and licensing

-(2.5)-(2.5)Global Generics net revenue increased 39 percent to $802.5 million in the third quarter.  Extended release product sales increased 89 percent to $341.7 million as a result of the launch of methylphenidate ER this year.  Third quarter international net revenue was $144.6 million, up 41 percent from the third quarter 2010, as a result of the addition of Specifar Pharmaceuticals in May and a larger number of product launches in key markets during the quarter.

Global Generics adjusted gross margin decreased 3.6 percentage points to 46.5 percent in the third quarter 2011 due to sales of methylphenidate ER at lower margins.

Global Generics R&D investment for third quarter 2011 was $54.6 million, consistent with prior year levels. Selling and marketing expenses for the third quarter 2011 increased $18.8 million to $45.3 million as a result of the addition of Specifar and higher selling and marketing expenses in certain other international markets.

Global Brands Segment InformationThree Months EndedNine Months EndedSeptember 30,September 30,(Unaudited; $ in millions)

2011201020112010Product sales

$
92.5$
82.4$
264.8$
231.7Other revenue

17.817.355.362.8Net revenue

110.399.7320.1294.5Operating expenses:Cost of sales

25.419.868.368.1Research and development

18.821.760.856.2Selling and marketing

40.834.3122.1102.2Segment contribution

$
25.3$
23.9$
8.9$
8.0Segment margin

22.9%24.0%21.5%23.1%Adjusted gross profit (1)

$
85.5$
79.9$
252.4$
226.4Adjusted gross margin

77.5%80.1%78.9%76.9%(1) Adjusted gross profit represents net revenue less

adjusted cost of sales and excludes amortization of

acquired intangibles. Pro forma adjustments for the

respective periods include the following: Acquisition and licensing

$
.6$
-$
.6$<
'/>"/>

SOURCE Watson Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13

Related medicine technology :

1. Watson Confirms Court Grants Preliminary Injunction Preventing Launch of Generic LOVENOX®
2. Watson to Present at the 2011 Annual Credit Suisse Health Care Conference
3. Watson Confirms Daytrana(R) Patent Challenge
4. Watson Provides Update on District Court Order Concerning Generic Version of LOVENOX®
5. Watson Confirms District Court Order Concerning Generic Version of LOVENOX(R)
6. Watson Confirms EMBEDA(R) Patent Challenge
7. Watson Launches Generic FEMCON(R) Fe
8. Watson to Host Conference Call and Webcast to Discuss Third Quarter 2011 Earnings
9. Watson to Present at the Jefferies 2011 Global Healthcare Conference
10. Watson Confirms Amphastar Patent Lawsuit
11. Watson Pharmaceuticals Announces Approval of Amphastars Generic LOVENOX(R)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/29/2014)... 2014  United Therapeutics Corporation (NASDAQ: UTHR ... the District of New Jersey ... against Sandoz, Inc. regarding United Therapeutics, Remodulin ® ... that U.S. Patent No. 6,765,117 is both valid and ... its generic product until the expiration of that patent ...
(Date:8/29/2014)... 2014 Diseases largely eradicated in ... returning. Measles was declared eliminated in 2000, yet the ... August 15—the highest incidence in 20 years. In July, ... whooping cough a problem of "epidemic proportions." ... dying from these preventable diseases—in part because some parents ...
(Date:8/29/2014)... Research and Markets has announced ... Market 2014-2018" report to their offering. ... that results in demyelination, axonal transection, and neurodegeneration. The ... by the immune system, which targets neurons within the ... disease in which the damage of the myelin sheath ...
Breaking Medicine Technology:District Court Decision Received In Remodulin Patent Case 2Vaccines at the Crossroads: Outbreaks On the Rise Across America 2Vaccines at the Crossroads: Outbreaks On the Rise Across America 3Global Multiple Sclerosis Drugs Market 2014-2018: Key Vendors are Bayer, Biogen Idec, Merck Serono, Novartis and Teva Pharmaceutical 2Global Multiple Sclerosis Drugs Market 2014-2018: Key Vendors are Bayer, Biogen Idec, Merck Serono, Novartis and Teva Pharmaceutical 3
... 9, 2011 /PRNewswire-USNewswire/ – CoMeD – On Friday, May ... filed an amendment to regulate vaccines containing mercury in ... buy, sell, manufacture, deliver, import, administer or distribute any ... or inorganic mercury per milliliter for children younger than ...
... 2011 Kinex Pharmaceuticals, LLC announced today that Dr. Allen ... decided to step aside as CEO. Dr. ... from a start-up biotechnology company with only a technology platform ... pre-IND to phase 2 developments. The recent collaboration established with ...
Cached Medicine Technology:Florida Legislature Refuses to Limit Mercury in Vaccines 2Florida Legislature Refuses to Limit Mercury in Vaccines 3The Board of Directors of Kinex Pharmaceuticals Appoints Dr. Allen Barnett as President Emeritus and Dr. Johnson Lau as Chief Executive Officer 2The Board of Directors of Kinex Pharmaceuticals Appoints Dr. Allen Barnett as President Emeritus and Dr. Johnson Lau as Chief Executive Officer 3
(Date:8/29/2014)... Angeles, CA (PRWEB) August 29, 2014 ... the expert knowledge and authenticity of its doctors. ... that only the most renowned doctors in their field ... helps to assure patients have a direct link to ... Patients and doctors will be able to communicate through ...
(Date:8/29/2014)... Denver, Colorado (PRWEB) August 29, 2014 ... by Daily Gossip reveals that the new program ... , The method was created by a ... this method to overcome the disturbing problem. Manuel ... developing and using this system. , Learn ...
(Date:8/29/2014)... Colorado (PRWEB) August 29, 2014 DailyGossip.org ... This is an absolutely unique method of curing multiple ... new program was created by Dr. Gary M. Levin, ... health specialist started to become interested in alternative remedies ... that classical remedies cannot be effective in all cases ...
(Date:8/29/2014)... CA (PRWEB) August 29, 2014 Dr. ... his plan to rename his practice to Parsa Mohebi ... Restoration has served the needs of hair loss patients ... traveled to its centers in Los Angeles, Beverly Hills, ... surgical and non surgical treatments, many of which Dr. ...
(Date:8/29/2014)... (PRWEB) August 30, 2014 Developed as ... DoudouneCanadienneGoosePasCher.fr’s high quality Canada Goose products offer ... when working on Arctic runways. The company’s Canada ... jackets in the current market. Additionally, the firm has ... special offer. , At present, all high quality ...
Breaking Medicine News(10 mins):Health News:Cosmetic Town Now Advocates for the Rights of Cosmetic Patients Using Novel Approach 2Health News:Nasal Polyps Treatment Miracle Review Exposes New Natural and Permanent Healing Program 2Health News:New Natural Multiple Sclerosis Treatment Review Reveals Gary M. Levin’s Unique Cure 2Health News:US Hair Restoration Changes Name to Parsa Mohebi Hair Restoration to Better Reflect Founder 2Health News:New Designs Of Canada Goose Chilliwack Bombers From DoudouneCanadienneGoosePasCher.fr 2
... as Titan of Business & ... ... Washington DC,business community leaders achieved extraordinary fundraising success on,Saturday ... guests,to the Washington Convention Center for one of DC,s largest ...
... Park Ridge, Ill. (April 3, 2008) Choline, an essential nutrient ... 24 percent reduced risk of breast cancer, according to a ... of Health (NIH), to be published in The FASEB Journals ... body of evidence that links egg consumption to a decreased ...
... like dementia are on the rise. And, thanks to ... will be at the forefront of research dealing with ... research teams have won National Health and Medical Research ... in hospitals, transitions to residential care and ascertaining the ...
... 3, 2008 TeamStaff, Inc.,(Nasdaq: TSTF ) ... today announced that it entered into a three ... agreement with Sovereign,Business Capital ("SBC", formerly Business Alliance ... loan credit facility, SBC takes,assignment of TeamStaff,s prior ...
... Edwards,Lifesciences Corporation (NYSE: EW ), a global ... disease, today announced that,its chairman and chief executive ... trading plan under Rule 10b5-1 of the Securities ... similar plan that expired last,month., The new ...
... degree made attempt, but economic status also plays role ... that promote quitting smoking are more likely to have ... dangers of secondhand smoke have a similar effect on ... Wisconsin study. , In 2002 and 2003, researchers ...
Cached Medicine News:Health News:DC's Business Leaders Raise $3.3 Million at Annual Leukemia Ball Featuring Jay Leno 2Health News:DC's Business Leaders Raise $3.3 Million at Annual Leukemia Ball Featuring Jay Leno 3Health News:DC's Business Leaders Raise $3.3 Million at Annual Leukemia Ball Featuring Jay Leno 4Health News:Essential nutrient found in eggs reduces risk of breast cancer by 24 percent 2Health News:Essential nutrient found in eggs reduces risk of breast cancer by 24 percent 3Health News:Better care for dementia patients through new funding 2Health News:TeamStaff Announces Amended Revolving Credit Facility with Sovereign Business Capital 2Health News:TeamStaff Announces Amended Revolving Credit Facility with Sovereign Business Capital 3Health News:Edwards Lifesciences' Chairman and CEO Adopts New 10b5-1 Stock Trading Plan to Replace Recently Expired Plan 2Health News:Better-Educated Smokers More Likely to Quit After Seeing Ads 2
The Maverick Over-The-Wire balloon catheter delivers a new level of performance to meet the changing demands of interventional cardiology....
The Maverick Over-The-Wire balloon catheter delivers a new level of performance to meet the changing demands of interventional cardiology....
... The Illuminated Phoroptor features lighted dials ... to perform refractions in the darkened setting ... pen light and leave the lights off ... features lighted sphere, cylinder power and cylinder ...
... The Reichert CT200 Tonometer ... the XCEL 250 and XCEL ... also compatible with other Zeiss-style ... mounted on the top of ...
Medicine Products: